US 10,940,194 B2 · Mutant of L1 protein of human papillomavirus type 58

Abstract

Provided are a mutated HPV58 L1 protein or a variant thereof, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein or a variant thereof and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types, and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

Claims26

Dependent claims

A mutated HPV58 L1 protein, wherein as compared with a wild type HPV58 L1 protein, the mutated HPV58 L1 protein has the following mutations:

(1) N-terminal truncation of 5-70 amino acids;
and
(2)(a) substitution of amino acid residues at positions 80-87 of the wild type HPV58 L1 protein with amino acid residues at the corresponding positions of the wild-type HPV33 L1 protein;
or
(2)(b) substitution of amino acid residues at positions 376-383 of the wild type HPV58 L1 protein with amino acid residues at the corresponding positions of the wild-type HPV33 L1 protein;
wherein said wild type HPV58 L1 protein has an amino acid sequence as set forth in SEQ ID NO:
1 or a sequence having 95% or greater identity to SEQ ID NO:
1;
and wherein said wild type HPV33 L1 protein has an amino acid sequence as set forth in SEQ ID NO:
2 or a sequence having 95% or greater identity to SEQ ID NO:
2.

8 more elements

A mutated HPV58 L1 protein, wherein as compared with a wild type HPV58 L1 protein, the mutated HPV58 L1 protein has the following mutations:

(1) N-terminal truncation of 5-70 amino acids;
and
(2)(a) substitution of amino acid residues at positions 80-87 of the wild type HPV58 L1 protein with amino acid residues at the corresponding positions of a wild-type HPV33 L1 protein;
and
(3)(a) substitution of amino acid residues at positions 375-383 of the wild type HPV58 L1 protein with the amino acid residues at the corresponding positions of a wild type HPV52 L1 protein;
or
(3)(b) substitution of amino acid residues at positions 144-168 of the wild type HPV58 L1 protein with amino acid residues at the corresponding positions of a wild type HPV52 L1 protein;
wherein said wild type HPV58 L1 protein has an amino acid sequence as set forth in SEQ ID NO:
1 or a sequence having 95% or greater identity to SEQ ID NO:1;
wherein said wild type HPV33 L1 protein has an amino acid sequence as set forth in SEQ ID NO:
2 or a sequence having 95% or greater identity to SEQ ID NO:2;
and wherein said wild type HPV52 L1 protein has an amino acid sequence as set forth in SEQ ID NO:
3 or a sequence having 95% or greater identity to SEQ ID NO:3.

10 more elements

Dependencies are inferred from the claim text.

Mutant of L1 protein of human papillomavirus type 58

Life of this patent

Mutant of L1 protein of human papillomavirus type 58

Life of this patent

Abstract

Claims26